Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure
rates exceeding 90% in children, it remains an important cause of morbidity and mortality in …

Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as
BCR-ABL1–like ALL, is a high-risk subset with a gene expression profile that shares …

Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk
subtype of ALL in children. There are conflicting data on the incidence and prognosis of Ph …

Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk
subtype characterized by genomic alterations that activate cytokine receptor and kinase …

Philadelphia chromosome (Ph)–like B-cell acute lymphoblastic leukemia (Ph-like ALL) is
associated with activated JAK/STAT, Abelson kinase (ABL), and/or phosphatidylinositol 3 …

New therapies for Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like
ALL) patients are urgently needed. The genetic landscape of Ph-like ALL is characterized by …

Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is a recently
described B-cell precursor ALL with a gene expression profile and a high frequency of IKZF1 …

Major advances in genetic and epigenetic profiling of acute lymphoblastic leukaemia (ALL)
have enhanced the understanding of key biological subsets of de novo and relapsed ALL …

Children with Down syndrome (DS) are prone to development of high-risk B-cell precursor
ALL (DS-ALL), which differs genetically from most sporadic pediatric ALLs. Increased …

Purpose Our aim was to determine the role of end-of-induction (EOI) minimal residual
disease (MRD) assessment in the identification and stratification of induction failure in …